Published in Blood Weekly, August 10th, 2006
Sarda is a seasoned CFO and previously held the CFO role of a U.S.-listed biotechnology company. He will be responsible for implementing the financial strategic plan, and completing the company's listing on the NASDAQ.
Sarda will report to the CEO, Dr. Hari Nair. "Subhash is known to the Street which will help us as part of our U.S. NASDAQ listing," said Nair. "He also has banking and other financial relationships which are important in our current acquisition phase," said Nair.
Sarda began his career at Ernst & Young in London, England, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.